1980
Advances in the multimodal primary management of cancer.
DeVita V, Henney J, Weiss R. Advances in the multimodal primary management of cancer. Advances In Internal Medicine 1980, 26: 115-29. PMID: 7013437.Peer-Reviewed Original Research
1979
The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon.
Weiss R, DeVita V. The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon. Journal Of The American College Of Surgeons 1979, 149: 267-71. PMID: 380029.Peer-Reviewed Original Research
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvival
1975
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Young R, Chabner B, Hubbard S, Canellos G, DeVita V. Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. National Cancer Institute Monograph 1975, 42: 145-8. PMID: 825777.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaOvarian carcinomaHigher overall response rateOral alkylating agentTrials of chemotherapyOverall response ratePAM therapyNational Cancer InstituteIntravenous cyclophosphamideSystemic chemotherapyRemission rateCombination therapyProspective trialsHigh-doseTherapeutic efficacyConventional treatmentResponse rateCancer InstituteChemotherapyAlkylating agentsCarcinomaTherapyTrialsCyclophosphamideMelphalan
1974
Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide
Young R, Canellos G, Chabner B, Schein P, Hubbard S, DeVita V. Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecologic Oncology 1974, 2: 489-497. PMID: 4376998, DOI: 10.1016/0090-8258(74)90059-6.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaComplete remissionMedian durationOvarian carcinomaLong-term disease-free survivalTerm disease free survivalHigh-dose cyclophosphamideDisease-free survivalProspective Randomized ComparisonDose cyclophosphamideIntravenous cyclophosphamideIntensive regimenMelphalan therapyFree survivalInitial remissionMedian survivalUnacceptable toxicityUntreated patientsAgent therapyRandomized comparisonPresent studyHigh dosePhenylalanine mustardRemissionChemotherapy